WO2003042190A1 - N-alkyl-adamantyl derivatives as p2x7-receptor antagonists - Google Patents
N-alkyl-adamantyl derivatives as p2x7-receptor antagonists Download PDFInfo
- Publication number
- WO2003042190A1 WO2003042190A1 PCT/IB2002/004043 IB0204043W WO03042190A1 WO 2003042190 A1 WO2003042190 A1 WO 2003042190A1 IB 0204043 W IB0204043 W IB 0204043W WO 03042190 A1 WO03042190 A1 WO 03042190A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- formula
- compounds
- hydrogen
- fluoro
- Prior art date
Links
- 0 C*(CCC1(CC(C)(C2)C3)CC3(*)CC2(*)C1)NC(c1c(*)ccc(N(C(N2*)=O)N=CC2=O)c1*)=O Chemical compound C*(CCC1(CC(C)(C2)C3)CC3(*)CC2(*)C1)NC(c1c(*)ccc(N(C(N2*)=O)N=CC2=O)c1*)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33689201P | 2001-11-12 | 2001-11-12 | |
US60/336,892 | 2001-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003042190A1 true WO2003042190A1 (en) | 2003-05-22 |
Family
ID=23318138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/004043 WO2003042190A1 (en) | 2001-11-12 | 2002-09-30 | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
Country Status (10)
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058270A1 (en) * | 2002-12-31 | 2004-07-15 | Pfizer Products Inc. | 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibitors for the treatment of inflammatory diseases |
WO2004092384A2 (en) * | 2003-04-17 | 2004-10-28 | Affectis Pharmaceuticals Ag | Means and methods for diagnosing and treating affective disorders |
WO2006003517A1 (en) * | 2004-06-29 | 2006-01-12 | Warner-Lambert Company Llc | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
WO2006003500A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
WO2006025783A1 (en) * | 2004-08-30 | 2006-03-09 | Astrazeneca Ab | Adamantyl derivates as p2x7 receptor antagonists |
WO2006059945A1 (en) * | 2004-11-30 | 2006-06-08 | Astrazeneca Ab | Novel compounds |
US7408065B2 (en) | 2003-06-02 | 2008-08-05 | Astrazeneca Ab | P2X7 receptor antagonists and their use |
EP2105164A1 (en) | 2008-03-25 | 2009-09-30 | Affectis Pharmaceuticals AG | Novel P2X7R antagonists and their use |
WO2010118921A1 (en) | 2009-04-14 | 2010-10-21 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
US7964616B2 (en) | 2007-03-22 | 2011-06-21 | Astrazeneca Ab | Compounds 679 |
EP2386541A1 (en) | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
CN104496968A (zh) * | 2015-01-13 | 2015-04-08 | 佛山市赛维斯医药科技有限公司 | 卤代金刚烷四氮唑结构的化合物、其制备方法和用途 |
US9221832B2 (en) | 2011-07-22 | 2015-12-29 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9388197B2 (en) | 2013-01-22 | 2016-07-12 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9388198B2 (en) | 2013-01-22 | 2016-07-12 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9409917B2 (en) | 2012-01-20 | 2016-08-09 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9556117B2 (en) | 2012-12-18 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as P2X7 receptor antagonists |
US9718774B2 (en) | 2012-12-12 | 2017-08-01 | Idorsia Pharmaceuticals Ltd | Indole carboxamide derivatives as P2X7 receptor antagonist |
US9951069B1 (en) | 2017-01-11 | 2018-04-24 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
US9988373B2 (en) | 2013-12-26 | 2018-06-05 | Shionogi & Co., Ltd. | Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same |
US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
US10774051B2 (en) | 2015-04-24 | 2020-09-15 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
US10919902B2 (en) | 2015-07-06 | 2021-02-16 | Alkermes, Inc. | Hetero-halo inhibitors of histone deacetylase |
US11066409B2 (en) | 2016-10-17 | 2021-07-20 | Shionogi & Co., Ltd. | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same |
US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020182646A1 (en) * | 2001-04-30 | 2002-12-05 | Ke Huazhu | Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders |
PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
US7071223B1 (en) * | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
SE0300480D0 (sv) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
WO2004099146A1 (en) * | 2003-05-12 | 2004-11-18 | Pfizer Products Inc. | Benzamide inhibitors of the p2x7 receptor |
EP1644042A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
RU2350354C2 (ru) * | 2003-05-29 | 2009-03-27 | Астразенека Аб | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТАГОНИСТ Р2Х7 РЕЦЕПТОРА И ФАКТОР НЕКРОЗА ОПУХОЛИ α |
SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
ITMI20040255A1 (it) * | 2004-02-17 | 2004-05-17 | Univ Degli Studi Milano | Sostanze ad attivita' antiangiogenica |
EP2343282B1 (en) * | 2004-03-05 | 2015-07-22 | F. Hoffmann-La Roche AG | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
JPWO2005107804A1 (ja) * | 2004-05-06 | 2008-03-21 | 小野薬品工業株式会社 | 呼吸器疾患治療剤 |
WO2006003513A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid |
WO2006035876A1 (ja) * | 2004-09-29 | 2006-04-06 | Kowa Co., Ltd. | 関節リウマチの予防及び/又は治療薬 |
WO2006083214A1 (en) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor |
JPWO2006104172A1 (ja) * | 2005-03-29 | 2008-09-11 | 興和株式会社 | 関節リウマチの予防及び/又は治療薬 |
WO2007008157A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 2 |
US20080207577A1 (en) * | 2005-07-11 | 2008-08-28 | Astrazeneca Ab | Combination I |
EP1924564B1 (en) | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
CN101300235B (zh) | 2005-09-01 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物 |
MX2008002731A (es) | 2005-09-01 | 2008-03-26 | Hoffmann La Roche | Diaminopirimidinas como moduladores de p2x3 y p3x2/3. |
JPWO2007049732A1 (ja) * | 2005-10-28 | 2009-04-30 | 興和株式会社 | 関節リウマチの予防及び/又は治療法 |
EP2033646A4 (en) * | 2006-06-29 | 2009-11-18 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
WO2009019503A2 (en) * | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | P2x7 antagonists for use in the treatment of mood disorders |
CN101842359A (zh) * | 2007-10-31 | 2010-09-22 | 日产化学工业株式会社 | 哒嗪酮化合物和p2x7受体抑制剂 |
WO2009108551A2 (en) * | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
JP5562716B2 (ja) * | 2010-05-12 | 2014-07-30 | 花王株式会社 | 電位依存性カチオンチャネル抑制剤 |
CN103304498B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 一种抗糖尿病化合物、其制备方法和用途 |
CN103304500B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 新型抗糖尿病化合物、其制备方法和用途 |
CN104478861B (zh) * | 2015-01-13 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | 一种硝基金刚烷四氮唑化合物、其制备方法和用途 |
CN104447703B (zh) * | 2015-01-13 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | 一种硝基金刚烷四氮唑化合物、其制备方法和用途 |
CN104478859B (zh) * | 2015-01-13 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | 一种羟基金刚烷四氮唑化合物、其制备方法和用途 |
CN104478860B (zh) * | 2015-01-13 | 2016-08-24 | 佛山市赛维斯医药科技有限公司 | 金刚烷四氮唑类衍生物、其制备方法和用途 |
CN104447704B (zh) * | 2015-01-13 | 2016-07-27 | 佛山市赛维斯医药科技有限公司 | 一种腈基金刚烷四氮唑化合物、其制备方法和用途 |
KR102035463B1 (ko) * | 2018-02-14 | 2019-11-26 | 연세대학교 산학협력단 | 암 줄기세포의 치료용 약학 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3789072A (en) * | 1970-04-22 | 1974-01-29 | Squibb & Sons Inc | Carboxamides |
WO1999029660A1 (en) * | 1997-12-05 | 1999-06-17 | Astrazeneca Uk Limited | Adamantane derivatives |
WO2000061569A1 (en) * | 1999-04-09 | 2000-10-19 | Astrazeneca Ab | Adamantane derivatives |
WO2001044213A1 (en) * | 1999-12-17 | 2001-06-21 | Astrazeneca Ab | New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
WO2001094338A1 (en) * | 2000-06-07 | 2001-12-13 | Astrazeneca Ab | Admantane derivatives |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU196892B (en) * | 1984-06-12 | 1989-02-28 | Fmc Corp | Herbicides containing as active substance derivatives of 2-phenil-1,2,4-triasine-3,5-dion and process for production of these derivatives |
US4766233A (en) * | 1984-06-12 | 1988-08-23 | Fmc Corporation | Herbicidal 2-aryl-1,2,4-triazine-3,5(2H,4H)-diones and sulfur analogs thereof |
US5128351A (en) * | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
US5077409A (en) * | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
BR9107169A (pt) | 1990-12-17 | 1993-11-16 | Shell Int Research | Derivados de isoquinolina fungicidas |
GB9119467D0 (en) | 1991-09-12 | 1991-10-23 | Smithkline Beecham Corp | Chemical compounds |
US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
US5686061A (en) | 1994-04-11 | 1997-11-11 | The Board Of Regents Of The University Of Texas System | Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors |
JP3144624B2 (ja) | 1995-06-02 | 2001-03-12 | 杏林製薬株式会社 | N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
WO1997023212A1 (en) | 1995-12-21 | 1997-07-03 | The Du Pont Merck Pharmaceutical Company | ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS |
ATE204857T1 (de) * | 1996-03-29 | 2001-09-15 | Searle & Co | Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
WO1998028269A1 (en) | 1996-12-23 | 1998-07-02 | Du Pont Pharmaceuticals Company | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS |
DE19701287A1 (de) * | 1997-01-16 | 1998-07-23 | Wernicke & Co Gmbh | Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben |
EP1019375A1 (en) | 1997-03-25 | 2000-07-19 | Astra Pharmaceuticals Limited | Novel pyridine derivatives and pharmaceutical compositions containing them |
WO1998043973A1 (de) | 1997-03-27 | 1998-10-08 | Novartis Ag | Zwischenprodukte und verfahren zur herstellung von pyrimidinderivaten |
DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
SE9704272D0 (sv) * | 1997-11-21 | 1997-11-21 | Astra Pharma Prod | Novel Compounds |
SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
JPH11318492A (ja) * | 1998-03-09 | 1999-11-24 | Aisin Seiki Co Ltd | 蛍光発生性基質を含有する組成物 |
US6320078B1 (en) | 1998-07-24 | 2001-11-20 | Mitsui Chemicals, Inc. | Method of producing benzamide derivatives |
FR2783519B1 (fr) | 1998-09-23 | 2003-01-24 | Sod Conseils Rech Applic | Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
EE200100317A (et) | 1998-12-16 | 2002-08-15 | Bayer Aktiengesellschaft | Uued bifenüül- ja bifenüülanaloogsed ühendid kui integriini antagonistid |
CA2382751A1 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
EP1088821A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
MXPA02005102A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Retro-anandamidas, ligandos de receptor de canabinoide de alta afinidad y estabilidad. |
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE10005284A1 (de) | 2000-02-07 | 2001-08-09 | Bayer Ag | Verfahren zur Herstellung von 1-Amino-3-aryl-uracilen |
-
2002
- 2002-09-30 WO PCT/IB2002/004043 patent/WO2003042190A1/en not_active Application Discontinuation
- 2002-10-03 MX MXPA02009783A patent/MXPA02009783A/es active IP Right Grant
- 2002-11-07 AT AT02257719T patent/ATE302196T1/de not_active IP Right Cessation
- 2002-11-07 ES ES02257719T patent/ES2244733T3/es not_active Expired - Lifetime
- 2002-11-07 EP EP02257719A patent/EP1310493B1/en not_active Expired - Lifetime
- 2002-11-07 BR BR0204588-5A patent/BR0204588A/pt not_active IP Right Cessation
- 2002-11-07 DE DE60205564T patent/DE60205564T2/de not_active Expired - Lifetime
- 2002-11-08 CA CA002411544A patent/CA2411544C/en not_active Expired - Fee Related
- 2002-11-12 US US10/292,886 patent/US6927219B2/en not_active Expired - Fee Related
- 2002-11-12 JP JP2002327661A patent/JP4001542B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3789072A (en) * | 1970-04-22 | 1974-01-29 | Squibb & Sons Inc | Carboxamides |
WO1999029660A1 (en) * | 1997-12-05 | 1999-06-17 | Astrazeneca Uk Limited | Adamantane derivatives |
WO2000061569A1 (en) * | 1999-04-09 | 2000-10-19 | Astrazeneca Ab | Adamantane derivatives |
WO2001044213A1 (en) * | 1999-12-17 | 2001-06-21 | Astrazeneca Ab | New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
WO2001094338A1 (en) * | 2000-06-07 | 2001-12-13 | Astrazeneca Ab | Admantane derivatives |
Non-Patent Citations (1)
Title |
---|
NARAYANAN V L: "ADAMANTYL ANALOGS OF 2'-(DIMETHYLAMINOPROPYLTHIO)CINNAMANILIDE", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 15, no. 11, 1972, pages 1180 - 1182, XP002938144, ISSN: 0022-2623 * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176202B2 (en) | 2002-12-31 | 2007-02-13 | Pfizer Inc. | Benzamide inhibitors of the P2X7 receptor |
WO2004058270A1 (en) * | 2002-12-31 | 2004-07-15 | Pfizer Products Inc. | 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibitors for the treatment of inflammatory diseases |
US7407956B2 (en) | 2002-12-31 | 2008-08-05 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
US6974812B2 (en) | 2002-12-31 | 2005-12-13 | Pfizer Inc. | Benzamide inhibitors of the P2X7 Ereceptor |
NL1025148C2 (nl) * | 2002-12-31 | 2007-09-28 | Pfizer Prod Inc | Benzamideremmers van de P2X7-receptor. |
EA008591B1 (ru) * | 2002-12-31 | 2007-06-29 | Пфайзер Продактс Инк. | Производные 3-(3,5-диоксо-4,5-дигидро-3h-(1,2,4)триазин-2-ил)бензамида в качестве ингибиторов p2xдля лечения воспалительных заболеваний |
US7767398B2 (en) | 2003-04-17 | 2010-08-03 | Affectis Pharmaceuticals Ag | Means and methods for diagnosing and treating affective disorders |
WO2004092384A3 (en) * | 2003-04-17 | 2005-06-02 | Affectis Pharmaceuticals Ag | Means and methods for diagnosing and treating affective disorders |
JP2010011855A (ja) * | 2003-04-17 | 2010-01-21 | Affectis Pharmaceuticals Ag | 情動障害の診断および治療のための手段および方法 |
WO2004092384A2 (en) * | 2003-04-17 | 2004-10-28 | Affectis Pharmaceuticals Ag | Means and methods for diagnosing and treating affective disorders |
US7408065B2 (en) | 2003-06-02 | 2008-08-05 | Astrazeneca Ab | P2X7 receptor antagonists and their use |
WO2006003500A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
WO2006003517A1 (en) * | 2004-06-29 | 2006-01-12 | Warner-Lambert Company Llc | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
WO2006025783A1 (en) * | 2004-08-30 | 2006-03-09 | Astrazeneca Ab | Adamantyl derivates as p2x7 receptor antagonists |
WO2006059945A1 (en) * | 2004-11-30 | 2006-06-08 | Astrazeneca Ab | Novel compounds |
US7964616B2 (en) | 2007-03-22 | 2011-06-21 | Astrazeneca Ab | Compounds 679 |
US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
EP2105164A1 (en) | 2008-03-25 | 2009-09-30 | Affectis Pharmaceuticals AG | Novel P2X7R antagonists and their use |
WO2010118921A1 (en) | 2009-04-14 | 2010-10-21 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
EP2386541A1 (en) | 2010-05-14 | 2011-11-16 | Affectis Pharmaceuticals AG | Novel methods for the preparation of P2X7R antagonists |
WO2011141194A1 (en) | 2010-05-14 | 2011-11-17 | Affectis Pharmaceuticals Ag | Novel methods for the preparation of p2x7r antagonists |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
US9221832B2 (en) | 2011-07-22 | 2015-12-29 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9409917B2 (en) | 2012-01-20 | 2016-08-09 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9718774B2 (en) | 2012-12-12 | 2017-08-01 | Idorsia Pharmaceuticals Ltd | Indole carboxamide derivatives as P2X7 receptor antagonist |
US9556117B2 (en) | 2012-12-18 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as P2X7 receptor antagonists |
US9388198B2 (en) | 2013-01-22 | 2016-07-12 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9388197B2 (en) | 2013-01-22 | 2016-07-12 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
US9988373B2 (en) | 2013-12-26 | 2018-06-05 | Shionogi & Co., Ltd. | Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same |
CN104496968A (zh) * | 2015-01-13 | 2015-04-08 | 佛山市赛维斯医药科技有限公司 | 卤代金刚烷四氮唑结构的化合物、其制备方法和用途 |
US10774051B2 (en) | 2015-04-24 | 2020-09-15 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
US11124486B2 (en) | 2015-04-24 | 2021-09-21 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same |
US11858939B2 (en) | 2015-07-06 | 2024-01-02 | Alkermes, Inc. | Hetero-halo inhibitors of histone deacetylase |
US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
US10919902B2 (en) | 2015-07-06 | 2021-02-16 | Alkermes, Inc. | Hetero-halo inhibitors of histone deacetylase |
US11066409B2 (en) | 2016-10-17 | 2021-07-20 | Shionogi & Co., Ltd. | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same |
US11685740B2 (en) | 2016-10-17 | 2023-06-27 | Shionogi & Co., Ltd. | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same |
US10696673B2 (en) | 2017-01-11 | 2020-06-30 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
US10793567B2 (en) | 2017-01-11 | 2020-10-06 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
US11225479B2 (en) | 2017-01-11 | 2022-01-18 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
US11286256B2 (en) | 2017-01-11 | 2022-03-29 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
US10519149B2 (en) | 2017-01-11 | 2019-12-31 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
US9951069B1 (en) | 2017-01-11 | 2018-04-24 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
US11912702B2 (en) | 2017-08-07 | 2024-02-27 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
Also Published As
Publication number | Publication date |
---|---|
US6927219B2 (en) | 2005-08-09 |
CA2411544C (en) | 2008-10-07 |
DE60205564D1 (de) | 2005-09-22 |
EP1310493A1 (en) | 2003-05-14 |
US20030144293A1 (en) | 2003-07-31 |
DE60205564T2 (de) | 2006-06-01 |
BR0204588A (pt) | 2003-09-16 |
EP1310493B1 (en) | 2005-08-17 |
JP4001542B2 (ja) | 2007-10-31 |
JP2003183263A (ja) | 2003-07-03 |
ATE302196T1 (de) | 2005-09-15 |
ES2244733T3 (es) | 2005-12-16 |
CA2411544A1 (en) | 2003-05-12 |
MXPA02009783A (es) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6927219B2 (en) | N-alkyl-adamantyl triazinyl benzamide derivatives | |
EP1448535B1 (en) | Benzamide and heteroarylamide as p2x7 receptor antagonists | |
AU2003285716B2 (en) | 3-(3,5-dioxo-4,5-dihydro-3H-(1,2,4)triazin-2-yl)-benzamide derivatives as P2X7-inhibitors for the treatment of inflammatory diseases | |
WO2004058731A1 (en) | Benzamide inhibitors of the p2x7 receptor | |
US20060217430A1 (en) | Benzamide inhibitors of the P2X7 receptor | |
AU2002347423A1 (en) | Benzamide and heteroarylamide as P2X7 receptor antagonists | |
TW200300083A (en) | Benzamide, heteroarylamide and reverse amides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |